University licences with royalties indexed to benefit and global access
When universities license cancer discoveries to companies, the contract would reward companies that price fairly and sell in poor countries, and penalise those that do not, using the royalty rate as the lever.
Technology transfer offices adopt a standard licence for oncology inventions in which the royalty rate steps down when the licensee meets access conditions (registration and tiered pricing in a list of low- and middle-income countries within two years of first approval, non-exclusive licensing to the Medicines Patent Pool for those markets) and steps up if the launch price exceeds a value-based reference. Since a large share of first-in-class cancer drugs originate in academic labs (including the checkpoint inhibitors and CAR-T), universities collectively hold leverage they rarely use. Universities Allied for Essential Medicines has drafted model clauses; the change is to make them the default for cancer.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- IdeaA regulator-endorsed standard contract for inter-company combination trials
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
- IdeaAn antitrust safe harbour for cross-company combination trials and data pooling
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
- IdeaA legal right to obtain marketed cancer drugs at cost for combination trials
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
- IdeaA permanent neutral non-profit sponsor for multi-company platform trials
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
- IdeaPatent term extension scaled to proven survival gain
Shares Transferable priority vouchers for first-in-class drugs, with price conditions, Incentives reward me-too drugs and marginal gains.
- TermBreakthrough Therapy / Priority Review / Priority Voucher
Shares Transferable priority vouchers for first-in-class drugs, with price conditions, Incentives reward me-too drugs and marginal gains.
- IdeaPublic-option manufacturing for essential generic cancer drugs in shortage
Shares Incentives reward me-too drugs and marginal gains, Most of the world has almost no cancer care.